{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:25:22Z","timestamp":1747203922567,"version":"3.40.5"},"posted":{"date-parts":[[2022,3,8]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,2,6]]},"abstract":"<title>Abstract<\/title>\n        <p><bold><italic>Purpose<\/italic>: <\/bold>Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient\u2019s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM.<bold><italic>Methods<\/italic>: <\/bold>Patients who met the trial\u2019s eligibility requirements were randomized and then administered either pyridoxine 100 mg twice daily or no pyridoxine, in both cases accompanied by their PLD-containing chemotherapeutic agent. Follow-up of patients was performed until the completion of induction therapy, the development of HFS or disease progression.<bold><italic>Results<\/italic>: <\/bold>Between January 1, 2017, and January 1, 2019, 105 patients were randomly assigned to the pyridoxine group (n = 52) or the no pyridoxine group (n = 53). In the pyridoxine and no pyridoxine groups, HFS developed after a median of four and three chemotherapeutic cycles, respectively. There were no grade 3 incidents recorded. Overall, 13.3% of patients experienced HFS (all grades). Eleven of 53 (20.7%) patients in the pyridoxine group experienced HFS, compared to 3 of 52 (5.7%) patients in the no pyridoxine group (p=0.042); there was no difference in HFS grades (p=0.725).<bold><italic>Conclusions<\/italic>: <\/bold>When administered concomitantly with PLD-containing chemotherapy, prophylactic pyridoxine is effective in reducing the incidence of HFS in patients with MM.<bold>Clinical Trial Registration<\/bold>: ChiCTR2100050294<\/p>","DOI":"10.21203\/rs.3.rs-1331081\/v1","type":"posted-content","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T22:01:51Z","timestamp":1646776911000},"source":"Crossref","is-referenced-by-count":0,"title":["Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-4731","authenticated-orcid":false,"given":"Juan","family":"Li","sequence":"first","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhe","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Meilan","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Beihui","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Junru","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gu","family":"Jingli","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang","family":"Lifen","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University First Affiliated Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-1331081\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-1331081\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T13:02:09Z","timestamp":1648645329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-1331081\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-1331081\/v1","relation":{},"subject":[],"published":{"date-parts":[[2022,3,8]]},"subtype":"preprint"}}